dm+d
429368003
Articles
Supply of emtricitabine/tenofovir disoproxil and raltegravir tablets for HIV Post Exposure Prophylaxis (HIV PEP): PGD template
5 October 2021A PGD template developed by SPS and the British Association of Sexual Health and HIV (BASHH) and British Association of HIV (BHIVA).
Switching between liquid and tablet/capsule formulations - Which medicines require extra care?
19 July 2021For a small number of medicines, there are differences in equivalent doses of oral formulations of the same medicine. This needs to be considered when…
Safety in Lactation: HIV infection
23 September 2020Breastfeeding by HIV-positive mothers may cause HIV infection in the infant and should be avoided where possible. The use of HIV drugs during breastfeeding is…
Medicine Compliance Aid Stability
IsentressMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Isentress
Tablets 400mg
G1 · Green 1Stability data indicates that the drug is suitable for CAs and there are no theoretical concerns with the product.
No special precautions for storage
Manufacturer confirms stability.
5 August 2015
IsentressMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Isentress
Tablets chewable 25mg, 100mg
R1 · Red 1Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Chewable tablets stored with dessicant in original pack.
15 February 2022
Lactation Safety Information
Specialist drug/complex disease area for which expert advice is recommended
21 September 2020